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1. INTRODUCTION 
 
The enhancement of oral bioavailability of poorly water soluble drugs remains 
one of the most challenging aspects of drug development. Although salt 
formation, solubilization, and particle size reduction have commonly been used to 
increase dissolution rate and thereby oral absorption and bioavailability of such 
drugs,1 there are practical limitations of these techniques. 
For drugs whose GI absorption is rate limited by dissolution, reduction of the 
particle size generally increases the rate of absorption and/or total bioavailability. 
This commonly occurs for drugs with poor water solubility. For example, the 
therapeutic dose of griseofulvin was reduced to 50% by micronization 2, and it 
also produced a more constant and reliable blood level. The commercial dose of 
spironolactone was also decreased to half by just a slight reduction of particle size 
3
. Such enhancement of drug absorption could further be increased several fold if 
a micronized product was used.3,4 
Poorly water soluble drugs are allied with slow drug absorption leading to 
inadequate and variable bioavailability and G.I. mucosal toxicity of drugs 5. 
Poorly water soluble drugs belong to BCS class II and Class IV 6 group of 
compounds. In the process of absorption of drug from oral route dissolution is the 
rate limiting step for poorly soluble drugs. In other words, in-vitro dissolution is 
the index of in-vivo absorption of poorly soluble drugs. Therefore it is necessary 
to enhance dissolution of these drugs to ensure maximum therapeutic utility of 
these drugs. 
In 1961, Sekiguchi and Obi7 developed a practical method whereby many of 
the limitations with the bioavailability enhancement of poorly water-soluble drugs 
just mentioned can be overcome. This method, which was later termed solid 
dispersion,8 involved the formation of eutectic mixtures of drugs with water-
soluble carriers by the melting of their physical mixtures. Sekiguchi and Obi7 
suggested that the drug was present in a eutectic mixture in a microcrystalline 
state. Later, Goldberg et al.9,10 demonstrated that all the drug in a solid dispersion 
might not necessarily be present in a microcrystalline state; a certain fraction of 
the drug might be molecularly dispersed in the matrix, thereby forming a solid 
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solution. In either case, once the solid dispersion was exposed to aqueous media 
and the carrier dissolved, the drug was released as very fine, colloidal particles. 
Because of greatly enhanced surface area obtained in this way, the dissolution rate 
and the bioavailability of poorly water-soluble drugs were expected to be high. 
The term solid dispersion refers to the dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by the melting 
(fusion), solvent, or melting-solvent method. The dispersion of a drug or drugs in 
a solid diluents or diluents by traditional mechanical mixing is not included in this 
category. The solid dispersions may also be called a solid-state dispersions, as first 
used by Mayersohn and gibaldi.11 
Over the years, solid dispersion included physiologically inert carriers to 
improve dissolution and bioavailability of poorly soluble drugs. In the present 
study, a modified solid dispersion approach was followed, where in a poorly 
soluble drug was solid dispersed in another freely soluble drug both available in a 
fixed dose combination and further, this modified approach did not utilize 
physiologically inert carriers. Hydrochlorothiazide and Losartan potassium, a 
fixed dose combination was selected as a model for this novel approach. 
Hydrochlorothiazide and Losartan potassium is one of the fixed dose 
combinations that have been effectively employed in the management of 
hypertension12. Losartan potassium is an angiotensin receptor blocker (ARB), and 
controls hypertension through this mechanism. Hydrochlorothiazide is a thiazide 
diuretic and it indicated along with the suitable antihypertensive drugs in the 
management of hypertension. Hydrochlorothiazide inhibits Na+ and Cl- 
reabsorption in the early distal tubule and collecting system14. Previously, solid 
dispersions of Hydrochlorothiazide were prepared using physiological inert 
carriers and their improved dissolution and their bioavailability was reported. 
Hydrochlorothiazide is poorly soluble whereas Losartan potassium is freely 
soluble in water. Owing to its poor solubility hydrochlorothiazide may pose 
dissolution rate limited absorption problem. An increase in dissolution rate of 
Hydrochlorothiazide effected by Losartan potassium in this novel approach will 
be beneficial for improving therapeutic efficacy of the combination14.  
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2. REVIEW OF LITERATURE 
Therapeutic effectiveness of a drug depends upon the bioavailability and 
ultimately upon the solubility of drug molecules. Solubility is one of the important 
parameters to achieve desired concentration of drug in systemic circulation for 
pharmacological response to be shown. Currently only 8% of new drug candidates 
have both high solubility and permeability.15The solubility of a solute is the maximum 
quantity of solute that can dissolve in a certain quantity of solvent or quantity of 
solution at a specified temperature. In other words the solubility can also be defined 
as the ability of one substance to form a solution with another substance. The 
substance to be dissolved is called as solute and the dissolving fluid in which the 
solute dissolve is called as solvent, which together form a solution. The process of 
dissolving solute into solvent is called as solution or hydration if the solvent is 
water.16 The transfer of molecules or ions from a solid state into solution is known as 
dissolution.  
Dissolution of drug is the rate-controlling step which determines the rate and 
degree of absorption. Drugs with slow dissolution rates generally show erratic and 
incomplete absorption leading to low bioavailability when administered orally. Since 
aqueous solubility and slow dissolution rate of BCS class II and class IV drugs is a 
major challenge in the drug development and delivery processes, improving aqueous 
solubility and slow dissolution of these Classes of drugs have been investigated 
extensively 17. A review of new monograph (1992-1995) in European pharmacopoeia 
shows that more than 40% of the drug substances have aqueous solubility below 
1mg/ml and the 32% have an aqueous solubility below 0.1mg/ml 18, 19. 
The dissolution rate of a drug is directly proportional to its solubility as per 
Noyes-Whitney equation and therefore solubility of a drug substance is a major factor 
that determines its dissolution rate and hence its absorption and bioavailability 
eventually 20. 
Noyes-Whitney equation illustrates how the dissolution rate of even very poorly 
soluble compounds might be improved to minimize the limitations to oral 
bioavailability: 
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dc/dt = AD. (Cs - C) / h 
Where, dc/dt is the rate of dissolution, A is the surface area available for dissolution, 
D is the diffusion coefficient of the compound, Cs is the solubility of the compound in 
the dissolution medium, C is the concentration of drug in the medium at time t, h is 
the thickness of the diffusion boundary layer adjacent to the surface of the dissolving 
compound21. 
 
TECHNIQUES OF SOLUBILITY ENHANCEMENT  
There are various techniques available to improve the solubility of poorly soluble 
drugs. Some of the approaches to improve the solubility are 22 
1) PHYSICAL MODIFICATIONS  
a) Particle size reduction  
 Micronization  
 Nanosuspension  
 Sonocrystalisation  
 Supercritical fluid process  
b) Modification of the crystal habit  
 Polymorphs  
 Pseudo polymorphs  
c) Drug dispersion in carriers  
 Eutectic mixtures  
 Solid dispersions  
 Solid solutions  
d) Complexation  
 Use of complexing agents  
e) Solubilization by surfactants:  
 Micro emulsions  
 Self micro emulsifying drug delivery systems  
2) CHEMICAL MODIFICATIONS  
 Salt form  
 Anhydrates  
 Solvates  
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3) OTHER METHODS  
 Cocrystalisation  
 Co solvency  
 Hydrotrophy  
 Solvent deposition  
 Selective adsorption on insoluble carrier  
 Use of soluble prodrug  
 Functional polymer technology  
 Porous micro particle technology  
 Nanotechnology approaches 
SOLID DISPERSIONS  
Solid dispersion was introduced in the early 1970s and refers to a group of 
solid products consisting of at least two different components, generally a hydrophilic 
matrix and a hydrophobic drug 23,24. Chiou and Riegelman defined the term solid 
dispersion as “a dispersion involving the formation of eutectic mixtures of drugs with 
water soluble carriers by melting of their physical mixtures”25, They classified solid 
dispersions into the following six representative types: Simple eutectic mixtures, solid 
solutions, glass solutions and glass suspensions, amorphous precipitations in a 
crystalline carrier, compound or complex formation, and combinations of the previous 
five types26 while Corrigan (1985) suggested the definition as being a ‘product formed 
by converting a fluid drug-carrier combination to the solid state’.27 
CLASSIFICATION OF SOLID DISPERSIONS: solid dispersion can be classified 
as follows 
1) First generation solid dispersions  
The first description of solid dispersions was given from Sekiguchi and Obi in 
1961 showed that formulation of eutectic mixtures improved the rate of drug release 
which in turn increases the bioavailability of poorly water soluble drugs. Later, Levy 
and Kaning developed solid dispersion systems, containing mannitol as carrier, by 
preparing solid solutions through molecular dispersions instead of using eutectic 
mixtures. They have the disadvantage of forming crystalline solid dispersions, which 
were more thermodynamically stable and did not release the drug as quickly as 
amorphous ones28. 
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2) Second generation solid dispersions 
It was noticed in the late sixties (Simonelli et al. 1969; Chiou and Riegelman, 
1969), that Solid dispersion with drug in the crystalline state is not as effective as 
amorphous because they are thermodynamically stable (Simonelli et al. 1969; 
Vippagunta et al. 2006; Urbanetz, 2006). Therefore, second generations of solid 
dispersions were introduced having amorphous carriers instead of crystalline. 
Formerly, the drugs were molecularly dispersed in amorphous carriers which are 
usually polymers in random pattern (Vilhelmsen et al. 2005)28. 
3) Third generation solid dispersions 
Third generation of solid dispersions appeared as the dissolution profile could 
be increased by using carriers having surface activity and self-emulsifying 
characteristics. These contain surfactant carriers or a mixture of amorphous polymers 
and a surfactant as carrier.  
The third generation solid dispersions stabilize the solid dispersions, increase 
the bioavailability of the poorly soluble drugs and reduce recrystallization of drug29. 
Surfactants have been included to stabilize the formulations, thus avoiding drug 
recrystallization and potentiating their solubility18. 
 
SIGNIFICANT PROPERTIES OF SOLID DISPERSION: 
There are certain parameters that are given below when successfully 
controlled, can produce improvements in bioavailability: 
1. Particle size reduction  
Solid dispersion represents the last state of the size reduction. It includes the 
principle of drug release by creating a mixture of poorly water soluble drug and 
highly soluble carriers, and after dissolution of carrier, the drug get molecularly 
dispersed in dissolution medium. 
2. Wettability 
Carriers having surface activity like cholic acid and bile salts, when used, can 
significantly increase the wettability properties of drug. Recently, in third generation 
solid dispersion surfactants have been included that is the emerging technique. 
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3. Higher porosity 
Solid dispersions containing linear polymers produce larger and more porous 
particles than those containing reticular polymers and therefore, result in a higher 
dissolution rate. 
4. Amorphous state of drug particles  
Drug particles in amorphous state have higher solubility30. 
ADVANTAGES OF SOLID DISPERSION 
1. Rapid dissolution rates that result in an increase in the rate and extent of the 
absorption of the drug, and a reduction in presystemic, both can lead to the 
need for lower doses of the drug. 
2. Other advantages include transformation of the liquid form of the drug into a 
solid form (e.g., clofibrate and benzoyl benzoate can be incorporated into PEG 
6000 to give a solid, avoidance of polymorphic changes and thereby bio-
availability problems), as in the case of nabilone and PVP dispersion, and 
protection of certain drugs by PEGs (e.g., cardiac glycosides) against 
decomposition by saliva to allow buccal absorption31. 
 
DISADVANTAGES OF SOLID DISPERSIONS  
 
 Despite extensive expertise with solid dispersions, they are not broadly used 
in commercial products, mainly because there is the possibility that during processing 
(mechanical stress) or storage (temperature and humidity stress) the amorphous state 
may undergo crystallization 32-34. The effect of moisture on the storage stability of 
amorphous pharmaceuticals is also a significant concern, because it may increase drug 
mobility and promote drug crystallization 20. Moreover, most of the polymers used in 
solid dispersions can absorb moisture, which may result in phase separation, crystal 
growth or conversion from the amorphous to the crystalline state or from a metastable 
crystalline form to a more stable structure during storage. This may result in 
decreased solubility and dissolution rate 35. Therefore, exploitation of the full 
potential of amorphous solids requires their stabilization in solid state, as well as 
during in vivo performance. Another drawback of solid dispersions is their poor scale-
up for the purposes of manufacturing.  
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LIMITATIONS OF SOLID DISPERSION SYSTEMS 
Problems limiting the commercial application of solid dispersion involve 
a. Its method of preparation, 
b. Reproducibility of its physicochemical properties,  
c. Its formulation into dosage forms, 
d. The scale up of manufacturing processes, and   
e. The physical and chemical stability of drug and vehicle. 
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Table 1 Classification of Carriers Enhancing Dissolution of Drugs 17 
 
  
 
 
 
S.No Category Example of Carriers 
 
1. 
 
Polymers 
 
Polyvinylpyrrolidone, Polyvinylpolypyrrolidone, 
Polyvinyl alcohol, Polyethylene glycols, Hydroxypropyl 
ethylcellulose, Hydroxypropyl cellulose, Poly (2-
hydroxyethylmethacrylate), Methacrylic copolymers 
(Eudragit® S100 sodium salts and Eudragit® L100 
sodium salts). 
 
2. 
 
Superdisintegrants 
Sodium starch glycolate, Croscarmellose sodium, Cross-
linked polyvinylpyrrolidone, Cross-linked alginic acid, 
Gellan gum, Xanthan gum, Calcium silicate. 
3. Cyclodextrins β-Cyclodextrins, Hydroxypropyl-β-cyclodextrins. 
 
4. 
 
Carbohydrates 
Lactose, Soluble starch, Sorbitol, Mannitol, β-(1-4)-2-
amino-2-deoxy-D-glucose (Chitosan), Maltose, 
Galactose, Xylitol, Galactomannan, British 
gum,Amylodextrin. 
 
5. 
 
Surfactants 
Poloxamers (Lutrol® F 127, Lutrol® F 68), 
Polyglycolized glyceride (Labrasol), Polyoxyethylene 
sorbitan monoesters (Tweens), Sorbitan esters (Spans), 
Polyoxyethylene stearates, Poly (beta-benzyl-L-aspartate) 
– b - poly (ethylene oxide), Poly (caprolactone) – b - poly 
(ethylene oxide). 
6. Hydrotropes Urea, Nicotinamide, Sodium benzoate, Sodium salicylate, 
Sodium acetate, Sodium-o-hydroxy benzoate, Sodium-p-
hydroxy benzoate, Sodium citrate. 
7. Polyglycolized 
glycerides 
Gelucire 44/14, Gelucire 50/13, Gelucire 62/05. 
8. Acids Citric acid, Succinic acid, Phosphoric acid. 
9. Dendrimers Starburst® polyamidoamine (PAMAM). 
  
 
 
 
10 
 
Table 2 Analytic method for characterization of solid forms 
 
 
S.No                Methods                          Significance 
1. 
Thermal analysis 
a. Cooling Curve Method 
b. Thaw Melt Method 
c. Thermo microscopic 
Method 
d. Zone Melting Method 
e. DSC Studies 
f. DTA Studies 
To study the morphology and degree of 
crystallinity. 
To find out the interaction between drug 
and carrier and formation of inclusion 
complex.  
2. X-ray Powder Diffraction Studies 
To find out the crystalline or amorphous 
form of drug. 
3. FTIR, NMR, Raman spectra 
To find out the complex formation 
between drug and carrier. 
4. Scanning Electron Microscopy To find out the particle size and shape. 
5. 
Dissolution rate / diffusion rate 
studies 
Rate and extent of dissolution. 
6. Thermodynamic study Degree of crystallinity 
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Fig.1 Methods of Preparation of Solid Dispersion 36 
        
 
                             
SOLVENT EVAPORATION METHOD 
Though different methods have been followed for preparation of solid 
dispersion, the solvent evaporation method assumes significance in the present study 
and so a brief review of this method is presented. Commonly used method of 
preparing a solid dispersion is the dissolution of drug and carrier in a common organic 
solvent, followed by the removal of solvent by evaporation.37-39Because the drug used 
for solid dispersion is usually hydrophobic and the carrier is hydrophilic, it is often 
difficult to identify a common solvent to dissolve both components. Large volumes of 
solvents as well as heating may be necessary to enable complete dissolution of both 
components. Chiou and Riegelman23 used 500 mL of ethanol to dissolve 0.5 g of 
griseofulvin and 4.5g of PEG 6000. Although in most other reported studies the 
volumes of solvents necessary to prepare solid dispersions were not specified, it is 
possible that they were similarly large. To minimize the volume of organic solvent 
necessary, Usui et al.40 dissolved a basic drug in a hydro alcoholic mixture of 1 N HCl 
and methanol, with drug to cosolvent ratios ranging from 1:48 to 1:20, because as a 
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protonated species, the drug was more soluble in the acidic cosolvent system than in 
methanol alone. Some other investigators dissolved only the drug in the organic 
solvent, and the solutions were then added to the melted carriers. Vera et al.41 
dissolved 1 g of oxodipine per 150mL of ethanol before mixing the solution with 
melted PEG 6000. In the preparation of piroxicam-PEG 4000 solid dispersion, 
Fernandez et al.42 dissolved the drug in chloroform and then mixed the solution with 
the melt of PEG 4000 at 70°C. Many different methods were used for the removal of 
organic solvents from solid dispersions. Simonelli et al.38evaporated ethanolic solvent 
on a steam bath and the residual solvent was then removed by applying reduced 
pressure. Chiou and Riegelman23 dried an ethanolic solution of griseofulvin and PEG 
6000 in an oil bath at 115 °C until there was no evolution of ethanol bubbles. The 
viscous mass was then allowed to solidify by cooling in a stream of cold air. Other 
investigators used such techniques as vacuum-drying,42,43 spray-drying,44-47 spraying 
on sugar beads using a fluidized bed-coating system,48 lyophilization,49 etc., for the 
removal of organic solvents from solid dispersions. None of the reports, however, 
addressed how much residual solvents were present in solid dispersions when 
different solvents, carriers, or drying techniques were used. 
 
Solvent  
Solvent to be included for the formulation of solid dispersion should have the 
following criteria: 
1. Both drug and carrier must be dissolved. 
2. Toxic solvents to be avoided due to the risk of residual levels after preparation  
E.g. chloroform and dichloromethane. 
3. Ethanol can be used as alternative as it is less toxic. 
4. Water based systems are preferred. 
5. Surfactants are used to create carrier drug solutions but as they can reduce 
glass transition temperature, so care must be taken in to consideration. 39 
 
Class I Solvents (Solvents to be avoided) 
Solvents included in this class are not to be taken in to use because of their deleterious 
environmental effects 
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Table. 3 List of some Class I Solvents. 
 
Solvent Concentration limit (ppm) Effect 
Benzene 2 Carcinogen. 
Carbon tetrachloride 4 Toxic and environmental 
Hazards. 
1,2-dichloroethane 5 Toxic. 
1,1-dichloroethane 8 Toxic. 
1,1,1-trichloroethane 1500 Environmental hazards. 
 
Class II Solvents (Solvents to be limited) 
These solvent should be limited used in pharmaceutical products because of 
their inherent toxicity.  
Table 4 Class II solvents in pharmaceutical products 
 
Solvent PDE(mg/day) Concentration limit(ppm) 
Chlorobenzene 3.6 360 
Chloroform 0.6 60 
Cyclohexane 38.8 3880 
1,2-dichloroethene 18.7 1870 
Ethylene glycol 6.2 620 
Methanol 30.0 3000 
Pyridine 2.0 200 
Toluene 8.9 890 
 
PDE= Permitted Daily Exposure 
 
Class III Solvents (Solvents with low toxic potential) 21 
Solvents included in this class may be regarded as less toxic and have the low 
risk to human health and as some are given in table 4. 
Class IV Solvents (Solvents for which no adequate toxicological data was found)  
Some solvents may also be of interest to manufacturers of excipients, drug 
substances, or drug products for example Petroleum ether, isopropyl ether. However, 
no adequate toxicological data on which to base a PDE was found21. 
 
 
  
 
 
 
Table 5 Class III solvents which should be limited by GMP or other quality based 
 
 
 
 
 
 
 
 
PHARMACOLOGY OF HYPERTENSION
Hypertension is generally known as high blood pressure, i.e. evaluation of the 
arterial blood pressure above the normal range expected in a particular age group. 
Hypertension may be of unknown cause (essential hypertension or 
may also result from kidney disease, including narrowing (stenosis) of the renal artery 
(renal hypertension), endocrine diseases (such as Cushing’s diseases or 
pheaochromocytoma) or disease of the arteries (such as coarctation of aorta), w
is known as secondary hypertension or symptomatic hypertension.
Acetic acid
Acetone 
1-Butanol
2-Butanol
Butyl acetate
Dimethylsulfoxide
Ethanol 
Ethylacetate
Ethyl ether
Formic acid
14 
requirements21 
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Fig.3: Schematic depiction of Pharmacology of Hypertension Processes 
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DRUGS AND MANAGEMENT OF HYPERTENSION 
           Table .6 Classification and Management of BP for Adults. 
Categories of drugs  
a. Diuretics 
i. Thiazides                   - Hydrochlorothiazide, chlorthalidone,  
                                      Indapamide.,                                                                  
ii. High ceiling diuretics - Furosemide. 
iii. Potassium sparing      -  Spironolactone, triamterene, amiloride. 
b. Angiotensin Converting Enzyme (ACE) inhibitors 
i. Captopril 
ii. Enalapril 
iii. Lisinopril 
iv. Perindopril 
v. Ramipril. 
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c. Angiotensin Receptor Blockers  
i. Losartan 
ii. Candesartan 
iii. Irbesartan. 
d. Calcium Channel Blockers 
i. Verapamil 
ii. Diltiazem 
iii. Lacidipine 
iv. Felodipine 
v. Amlodipine 
vi. Nifedipine. 
e. β Adrenergic Blockers 
i. Propranolol, 
ii. Metaprolol, 
iii. Atenolol. 
Works done so far to improve solubility of Hydrochlorothiazide  
1. Solid dispersions of hydrochlorothiazide in mannitol and in 
dihydroxypropyltheophylline were prepared by melting and solvent methods.    
(Abdel-Fattah et al., 1986)50.    
2. Binding of hydrochlorothiazide to milk improves its solubility. (Antimisiaris 
et al., 1989)51. 
3. Influence of Sodium Caseinate on the Dissolution Rate of 
Hydrochlorothiazide and Chlorothiazide. (Millar.F.c et al., 1991)52. 
4. Formulation and production of rapidly disintegrating tablets by lyophilisation 
using hydrochlorothiazide as a model drug. (Jean Paul Remon et al., 1997)53. 
5. Bioavailability of hydrochlorothiazide pellets made by extrution, 
Spheronisation, containing polyethelene glycol 400 as a dissolution enhancer. 
(Christvervaet et al.,  1997)54. 
6. Valsartan and Hydrochlorothiazide alone and in Combination on Blood 
Pressure and Heart Rate in Conscious-Telemetered Spontaneously 
Hypertensive Rats (SHR) (Randy L.Webb et al., 1997)55. 
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7. Solubility of chlorothiazide was improved in the presence of gelatin. 
(Antimisiaris et al., 2001)56. 
8. Direct moulding of isomalt co-extruded with either paracetamol or 
Hydrochlorothaizide  has shown improved dissolution rate of 
Hydrochlorothiazide. (Ndindayino et al., 2001)57. 
9. Liquisolid formulations of hydrochlorothiazide tablets showed significantly 
greater extent   absorption and bioavailability than the commercial tablets 
which was evaluated in beagle dogs (Khaled et al., 2001)58. 
10. Enhancing dissolution of hydrochlorothiazide using superdisintegrants 
(Sodium starch glycolate, Croscarmellose sodium) by direct compression. 
(Zhao et al., 2005)59. 
11. A novel drug-drug solid dispersion of hydrochlorothiazide-losartan potassium 
(N.N Rajendran., et al 2010)60. 
12. Micelles from PEO–PPO–PEO block copolymers as nanocontainers for 
solubilization of a poorly water soluble drug hydrochlorothiazide.( Yogesh 
Kadam et al.,2010)61.  
13. Pharmaceutical composition of Hydrochlorothiazide and β-cyclodextrin was 
prepared by spray-drying, freeze-drying and fluid bed drying to improve water 
solubility and bioavailability of hydrochlorothiazide. (Maria Arlete Silva Pires 
et al., 2011)62. 
14. Preparation of microparticles of hydrochlorothiazide by spray drying. (R.M. 
Martins et al., 2011)63. 
15. Solid dispersion of Hydrochlorothiazide – Captopril has improved 
bioavailability of hydrochlorothiazide by wet granulation method. 
(Padmapriya et al., 2011)64. 
16. Pellets made with co-processed MCC-Eudragit_ E incorporating the higher 
proportion of sorbitol (50%) show a very high dissolution rate of 
hydrochlorothiazide (HCT) and undergo rapid disintegration in the dissolution 
medium. (Ramón Martínez-Pacheco et al., 2011)65. 
 
 
 
  
 
 
 
19 
 
BACKGROUND OF THE STUDY: 
 
Literature survey indicates that over the years solid dispersion approach has 
been applied to poorly soluble drugs using physiologically inert carriers with a view 
to improve dissolution and bioavailability of these drugs. In recent past a novel drug-
drug solid dispersion of Hydrochlorothiazide – Losartan potassium has been reported 
and improved dissolution of poorly soluble hydrochlorothiazide has also been 
documented. An improved pharmacodynamic activity of Hydrochlorothiazide, 
through this novel solid dispersion approach has also been established (unpublished 
data). Many approaches have been followed earlier to improve solubility (or) 
dissolution of Hydrochlorothiazide50-65. Pharmacokinetic profile of this novel solid 
dispersion of Hydrochlorothiazide - Losartan potassium will help understand its 
influence on improved dissolution and pharmacokinetic property and therefore, the 
present study was directed to investigate the pharmacokinetics of 
Hydrochlorothiazide as compared to physical mixture and corresponding commercial 
tablet dosage form. 
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                      3. AIM AND OBJECTIVE   
 
 
AIM: 
    To investigate In-vitro dissolution and In-vivo bioavailability of a novel drug– drug     
    solid dispersion of Hydrochlorothiazide – Losartan potassium. 
 
 
OBJECTIVE 
The following parameters were estimated  
 Preparation of physical mixtures (1:2, 1:4, 1:8 ratios). 
 Preparation of solid dispersions (1:2, 1:4, 1:8 ratios). 
 Phase solubility study of Hydrochlorothiazide - Losartan potassium in 
deaerated water. 
 FTIR analysis of pure drugs, physical mixtures and solid dispersions. 
 DSC of pure drugs, physical mixtures and solid dispersions. 
 In-vitro dissolution of pure drugs, physical mixtures and solid dispersions. 
 In-vivo pharmacokinetic study of Hydrochlorothiazide from best In-vitro 
formulation. 
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4. PLAN OF WORK 
PREFORMULATION STUDY 
         ESTIMATION OF DRUGS     PREPARATIONS    EVALUATIONS 
METHOD I 
Calibration curve of 
hydrochlorothiazide 
METHOD II 
Mixed standard 
calibration curve 
      PHYSICAL MIXTURE 
(Hydrochlorothiazide and Losartan 
potassium [1:2, 1:4, 1:8]) 
      SOLID DISPERSION 
(Hydrochlorothiazide and Losartan 
potassium [1:2, 1:4, 1:8]) 
Phase solubility 
study 
FTIR analysis 
DSC analysis 
In-vitro dissolution 
study 
In-vivo pharmacokinetic 
study of the best formulation 
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                                 5. DRUG PROFILES 
HYDROCHLOROTHIAZIDE 
 
C7H8ClN3O4S2                                                                    Molecular weight .297.73 
Hydrochlorothiazide is 6 chloro,-3, 4-dihydro-2, 4-1, 2, 4-benzothiazide-7-
sulfonamide1, 1 dioxide.  
Category            : Diuretic 
Description : white, crystalline powder odorless.  
 Solubility             : soluble in acetone, methanol, and dimethyl formamide,  
                                              Sparingly soluble in ethanol, very slightly soluble in               
                                              water,  insoluble in ether and   in chloroform.   
Pharmacology 
Hydrochlorothiazide is a thiazide type diuretic. This group of diuretic 
agent is actively transported by a probenecid-sensitive secretory mechanism in to the 
proximal tubule. They act on the luminal membrane of the cortical diluting segments 
of the distal convoluting tubule and inhibit specific Na+ and Cl-
 
reabsorption. A 0.3% 
of diuretic action to be the result of carbonic anhydrase inhibition in the proximal 
tubule, resulting in decreased Na+ and HCO3 – reabsorption. The antihypertensive 
effect of diuretic is by modulating the activity of K+ channels. ATP regulated K+ 
channels in resistance arterioles may be activated by thiazide. This action leads to 
membrane hyper polarization, which opposes the smooth muscle Ca2+ entry and 
contraction and reduces peripheral vascular resistance.The other mechanism in 
reducing blood pressure is by contraction of extra cellular volume (ECV), reduced 
cardiac outputs and peripheral vascular resistance. Hydrochlorothiazide Also 
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increases HCO3- , PO4-,Mg2+ excretion (proximal tubule)and Na+,Cl-,2K+ 
excretion(distal tubule). By contrast, calcium excretion is decreased with increase in 
plasma urate concentration through an enhanced reabsorption of urate in the 
proximal tubule and decreased excretion of urate by the tubular cells.  
Pharmacokinetics 
Following an oral dose little is absorbed from the stomach. Food and the 
volume of fluid do not affect absorption. Plasma protein binding of 
Hydrochlorothiazide is 40-60%. It is highly concentrated in erythrocytes as a result 
of binding to carbonic anhydrase. Peak plasma concentration is attained after 2-4 hrs 
of dosing. Volume of distribution is 0.83-301 lit/kg. Onset of diuresis occurs with in 
2hrs of administration and lasts 6-12 hrs. Onset of antihypertensive effect is over 3-4 
days. It is not metabolized in man and is excreted unchanged almost entirely 95% in 
the urine. It crosses the placental barrier and is excreted in breast milk. 
 Uses and administration 
1. Edema 
2. Control of hypertension 
3. Management of diabetic insipidus. 
4. Management of proximal renal tubular acidosis. 
5. Idiopathic hypercalcaemia of calcium nephrolithiasis. 
Contraindications  
1. Anuria 
2. Renal impairment 
3. Diabetes mellitus 
4. Hyperlipidema 
5. Gout  
6. Systemic lupus erythematous 
7. Electrolyte imbalance.  
 
 
  
 
 
 
24 
 
Adverse reactions 
1. Hyponatremia 
2. Hypokalemia 
3. Acute saline depletion 
4. GIT-disturbances 
5. Hearing loss 
6. Allergic manifestations 
7. Hyperuricaemia 
8. Hyperglycemia 
9. Hypercalcaemia 
10. Hyperlipidemia 
11. Magnesium depletion.  
Hydrochlorothiazide available in combination with various antihypertensive agents 
namely captopril, enalapril, lisopril, timolol, sotalol, metaprolol tartrate, propranolol 
HCl.  
Diuretics In Hypertension 
The initial reduction in blood pressure during the first weeks of diuretic 
therapy is due to volume depletion. During this period, cardiac output falls, because of 
venous return. Total peripheral resistance is unchanged and plasma rennin activity 
increase. The long term antihypertensive effect of diuretic is the result of diminished 
vascular responsiveness to sympathetic nervous stimulation. Aoki and broadi (1969) 
demonstrated that antihypertensive effect of diuretics is mainly due to direct action on 
the resistance and capatacitance vessels. Diuretics produce antihypertensive effects by 
modulating the activity of K+ channels. ATP regulated K+ channels in resistance 
arterioles may be activated by thaizides. This action leads to membrane hyper 
polarization, which opposes smooth muscle Ca2+ entry and contraction and reduces 
peripheral vascular resistance. 
Changes in extra cellular and intracellular electrolyte relationship resulting in 
diminished arteriolar tonicity reflected as reduction in TPR. 
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Green et al., (1961) demonstrated that a decrease in total circulation plasma volume 
due to thaizide diuretic resulted in diminished cardiac filling and reduced cardiac 
output. 
Feisal (1961) indicated that decrease in BP was due to decreased response to 
endogenous vasopressor mechanism and by vasodilatation. 
 
Table.7 Marketed preparations of Hydrochlorothiazide with losartan potassium 
 
LOSARTAN POTASSIUM 
 
C22H22ClKN6O     Molecular weight .461.01 
        2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-
imidazole-5-methanol monopotassium salt. 
 
 
Zaart H 
 
Cipla 
Hy     Hydrochlorothiazide 25 mg 
Los    Losartan potassium 50mg 
 
Losar H 
 
Unichem 
 
Hydrochlorothiazide 12.5 mg 
             Losartan potassium 50mg 
Covance 
 
Ranboxy 
Hydrochlorothiazide 25 mg 
Losartan potassium 50mg. 
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Category  : Antihypertensive   
Description       :        White to off-white free-flowing crystalline powder 
Solubility    :         freely soluble in water, soluble in alcohols, and slightly                                              
                                    Soluble in organic solvents, such as acetonitrile and methyl      
                                    ethyl ketone. 
Pharmacology 
Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin 
converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary 
vasoactive hormone of the renin-angiotensin system and an important component in 
the pathophysiology of hypertension. It also stimulates aldosterone secretion by the 
adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor 
and aldosterone-secreting effects of angiotensin II by selectively blocking the binding 
of angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth 
muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is 
not known to be associated with cardiovascular homeostasis. Both losartan and its 
principal active metabolite do not exhibit any partial agonist activity at the AT1 
receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than 
for the AT2 receptor. In vitro binding studies indicate that losartan is a reversible, 
competitive inhibitor of the AT1 receptor. The active metabolite is 10 to 40 times more 
potent by weight than losartan and appears to be a reversible, non-competitive inhibitor 
of the AT1 receptor. 
Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that 
converts angiotensin I to Angiotensin II and degrades Bradykinin); nor do they bind to 
or block other hormone receptors or ion channels known to be important in 
cardiovascular regulation. 
Pharmacokinetics 
                  Losartan is an orally active agent that undergoes substantial first-pass 
metabolism by cytochrome P450 enzymes. It is converted, in part, to an active 
carboxylic acid metabolite that is responsible for most of the angiotensin II receptor 
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antagonism that follows losartan treatment. Losartan metabolites have been identified 
in human plasma and urine. In addition to the active carboxylic acid metabolite, 
several inactive metabolites are formed. Following oral and intravenous administration 
of 14C-labeled losartan potassium, circulating plasma radioactivity is primarily 
attributed to losartan and its active metabolite. In vitro studies indicate that cytochrome 
P450 2C9 and 3A4 are involved in the biotransformation of losartan to its metabolites. 
Minimal conversion of losartan to the active metabolite (less than 1% of the dose 
compared to 14% of the dose in normal subjects) was seen in about one percent of 
individuals studied. 
The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-
9 hours.  
The pharmacokinetics of losartan and its active metabolite are linear with oral 
losartan doses up to 200 mg and do not change over time. Neither losartan nor its 
metabolite accumulates in plasma upon repeated once-daily dosing. 
Following oral administration, losartan is well absorbed (based on absorption 
of radio labeled losartan) and undergoes substantial first-pass metabolism; the systemic 
bioavailability of losartan is approximately 33%. About 14% of an orally-administered 
dose of losartan is converted to the active metabolite. Mean peak concentrations of 
losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. 
While maximum plasma concentrations of losartan and its active metabolite are 
approximately equal, the AUC of the metabolite is about 4 times as great as that of 
losartan. A meal slows absorption of losartan and decreases its Cmax but has only 
minor effects on losartan AUC or on the AUC of the metabolite (about 10% 
decreased). 
The pharmacokinetics of losartan and its active metabolite were also 
determined after IV doses of each component separately in healthy volunteers. The 
volume of distribution of losartan and the active metabolite is about 34 liters and 
12 liters, respectively. Total plasma clearance of losartan and the active metabolite is 
about 600 mL/min and 50 mL/min, respectively, with renal clearance of about 
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75 mL/min and 25 mL/min, respectively. After single doses of losartan administered 
orally, about 4% of the dose is excreted unchanged in the urine and about 6% is 
excreted in urine as active metabolite. Biliary excretion contributes to the elimination 
of losartan and its metabolites. Following oral 14C-labeled losartan, about 35% of 
radioactivity is recovered in the urine and about 60% in the feces. Following an 
intravenous dose of 14C-labeled losartan, about 45% of radioactivity is recovered in 
the urine and 50% in the feces. 
Both losartan and its active metabolite are highly bound to plasma proteins, 
primarily albumin, with plasma free fractions of 1.3% and 0.2%, respectively. Plasma 
protein binding is constant over the concentration range achieved with recommended 
doses. 
Indications and Usage 
   Treatment of hypertension; nephropathy in type II diabetic patients; reduce 
risk of stroke in patients with hypertension and left ventricular hypertrophy. 
Dosage and Administration 
Hypertension 
Adults Initial dose  
PO 50 mg/day; 25 mg/day if volume depleted or history of hepatic impairment. 
Maintenance dose  
PO 25 to 100 mg/day. 
Children 6 yr of age and older Initial dose  
PO 0.7 mg/kg (max, 50 mg) once daily. 
Maintenance dose  
PO 0.7 to 1.4 mg/kg/day (max, 100 mg). 
Nephropathy in Type 2 Diabetes Adults Initial dose  
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PO 50 mg/day; the dose may be increased to 100 mg/day based on BP response. 
Drug Interactions 
Losartan, administered for 12 days, did not affect the pharmacokinetics or 
Pharmacodynamics of a single dose of Warfarin. Losartan did not affect the 
pharmacokinetics of oral or intravenous Digoxin. There is no Pharmacokinetic 
interaction between Losartan and Hydrochlorothiazide. Co-administration of Losartan 
and Cimetidine led to an increase of about 18% in AUC of losartan but did not affect 
the pharmacokinetics of its active metabolite. Co-administration of losartan and 
Phenobarbital led to a reduction of about 20% in the AUC of losartan and that of its 
active metabolite. A somewhat greater interaction (approximately 40% reduction in the 
AUC of active metabolite and approximately 30% reduction in the AUC of losartan) 
has been reported with Rifampin. Fluconazole, an inhibitor of cytochrome P450 2C9, 
decreased the AUC of the active metabolite by approximately 40%, but increased the 
AUC of losartan by approximately 70% following multiple doses. Conversion of 
losartan to its active metabolite after intravenous administration is not affected by 
Ketoconazole, an inhibitor of P450 3A4. The AUC of active metabolite following oral 
losartan was not affected by erythromycin, another inhibitor of P450 3A4, but the 
AUC of losartan was increased by 30%. 
Contraindications 
Losartan is contraindicated in patients who are hypersensitive to any component of this 
product. 
Adverse reactions 
• Fetal/Neonatal Morbidity and Mortality. 
• Hypotension — Volume-Depleted Patients. 
• Hypertensive Patients with Left Ventricular Hypertrophy. 
• Nephropathy in Type 2 Diabetic Patients. 
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The following additional adverse reactions have been reported in post marketing 
experience: 
• Digestive: Hepatitis (reported rarely). 
• Hemic: Thrombocytopenia (reported rarely). 
• Hypersensitivity: Angioedema. 
• Metabolic and Nutrition: Hyperkalemia, Hyponatremia. 
• Musculoskeletal: Rare cases of Rhabdomyolysis. 
• Nervous system disorders: Dysgeusia. 
• Skin: Erythroderma. 
• Respiratory: Dry cough. 
Table.8 Commercial products 
 
    Losartas  -50mg  - Tab 
    Covance    -50mg  - Tab 
                          Zaart  - 50mg  - Tab 
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6. MATERIALS AND METHODS 
Table.9 
 
 
 
Table.10 
 
 
 
 
 
S.no            Equipments Manufactures/suppliers 
    1.  
UV – Spectrophotometer 
 
Perkin Elmer 
    2.  
Infra-Red  Spectrophotometer 
 
Perkin Elmer spectrum RX1 FT-IR 
    3.  
Differential Scanning Calorimetry 
 
Schimadzu, DSC 60. 
    4.  
Weighing Balance 
 
Schimadzu 
    5.  
Dissolution Apparatus (USP) 
 
Veego 
S.no Drugs and chemicals Manufactures/suppliers 
    
      1. 
 
Hydrochlorothiazide USP 
 
Medrich Pvt. Ltd.  
    
      2. 
 
Losartan potassium   USP 
 
Medrich Pvt. Ltd. 
    
     3. 
 
Methanol  
 
Loba Chemie Pvt.Ltd. 
    
     4. 
 
Tragacanth  
 
Loba Chemie Pvt.Ltd. 
    
     5. 
 
Alcohol  
 
Loba Chemie Pvt.Ltd. 
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7. METHODOLOGY 
7.1 ESTIMATION OF PURE DRUGS, PHYSICAL MIXTURES AND SOLID   
DISPERSIONS 
Method I 
 Pure sample of Losartan and potassium were analyzed by Spectrophotometric 
method as described by M.Gandhimathi et.al. 66 
Preparation of Standard Solutions 
 Standard solution of 100mg each of Losartan potassium and 
Hydrochlorothiazide were made using methanol. 
Mixed Standards 
100mg of Losartan potassium and Hydrochlorothiazide standard solution were 
used in the mixed standards. The concentrations of the two components in the mixed 
standards are reported. All the mixed standard solutions were scanned in the range of 
200-400 nm using the sample points 236 for Losartan potassium and 270nm for 
Hydrochlorothiazide. A standard curve was constructed by plotting the absorbance vs. 
concentration of the drug taken.  
Method II 
This method was adapted to pure Hydrochlorothiazide.100mg 
Hydrochlorothiazide was accurately weighed and dissolved in methanol in standard 
flask and diluted to 100ml with methanol. Further, dilutions were made to get 2, 4, 6, 
8, 10µg/ml HCT and this solution was scanned at 270nm to obtain absorbance. 
Standard curve was constructed by plotting absorbance vs concentration of drug 
7.2 PREPARATION OF PHYSICAL MIXTURE AND SOLID DISPERSION: 
 Preparation of physical mixture 
             Hydrochlorothiazide and Losartan potassium were   accurately weighed at the 
ratio of 1:2, 1:4; 1:8 (12.5: 25mg, 12.5: 50mg, 12.5: 100mg) pulverized, and then 
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mixed thoroughly in a glass mortar with pestle until homogenous. The mixtures were 
passed through a 250µm sieve for further experiment. 
 Preparation of solid dispersion 
Solid dispersion of Hydrochlorothiazide and Losartan potassium at three ratios 
of 1:2, 1:4, 1:8 (12.5:25mg, 12.5:50mg, 12.5:100mg) was prepared by solvent method. 
Hydrochlorothiazide and Losartan potassium were dissolved in methanol and mixed 
with magnetic stirring. Solvent was evaporated at reduced pressure a 40oC in a rotatory 
evaporation apparatus. Subsequently solid dispersion was stored vaccum over silica gel 
for 12hrs at room temperature. After dried solid dispersion was passed through a 
250µm sieve. Sample was stored in a desiccator and used for further investigation. 
Table 11 Formulation of physical mixtures and solid dispersions of     
Hydrochlorothiazide - Losartan potassium. 
 
 
 
 
7.3Evaluation of formulations   
The prepared formulations of solid dispersion and physical mixture were evaluated for 
the following          
a. Physico-chemical characterization. 
b. In vitro dissolution study. 
c. In vivo pharmacokinetic study. 
7.3.1 PHYSICO CHEMICAL CHARACTERIZATION: 
Before formulation of drug substances into a dosage form, it is essential that 
drug polymer should be chemically and physically characterized. Preformulation 
studies give the information needed to define the nature of the drug substance and 
S.No  Physical mixture (HTC:LSP)  Solid dispersion (HTC:LSP) 
1.       1:2 F1PM       1:2 F1SD 
2.       1:4 F2PM       1:4 F2SD 
3.       1:8 F3PM       1:8 F3SD 
  
 
 
 
34 
 
provide a framework for the drug combination with pharmaceutical carrier in the 
fabrication of a dosage form. 
Compatibility study: 
One of the requirements for the selection of suitable excipients or carrier for 
pharmaceutical formulation is its compatibility. Therefore in the present work the 
compatibility study was carried out by using FTIR spectrophotometer to find out any 
possible chemical interaction of Hydrochlorothiazide and Losartan potassium in 
physical mixture and solid dispersion. 
 Compatibility between the drugs was determined by using Perkin Elmer 
spectrum RX1 FT-IR spectrometer model. The pellets were prepared at high 
compaction pressure by using KBr and the ratio of sample to KBr is 1:100.The pellets 
thus prepared were examined and the spectra of drug and other ingredients in the 
formulations were compared with that of the spectra of pure drugs.  
7.3.2 Determination of phase solubility of Hydrochlorothiazide / Losartan 
potassium in Deaerated water.  
 Excessive amount of pure Hydrochlorothiazide (250mg) was added to 
100mL of Deaerated Water containing varying concentrations of Losartan potassium 
(0025%, 0.005%, 0.01% w/v) in stoppered flasks. These suspensions were equilibrated 
by intermittent shaking for 72hrs maintained at 37±2oC. These suspensions were 
filtered through a Whatman filter. The concentration of Hydrochlorothiazide was 
determined by method I described earlier and reported.  
7.3.3 Differential Scanning Calorimetry (DSC) 
  Differential Scanning Calorimetry (DSC) curve of Hydrochlorothiazide, 
Losartan potassium, physical mixtures and solid dispersions were measured with a 
DSC instrument (Mettler Tolero Model). The samples were accurately weighed and 
heated in closed aluminum crimped cells at a rate of 10oC.min-1 between 30 and 300oC 
temperature under a nitrogen gas flow of 40mL.min-1during study. 
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7.3.4 Invitro Dissolution study  
Dissolution profile of pure Hydrochlorothiazide, physical mixture and solid 
dispersion were evaluated according to the method described in USFDA. 900mL of the 
dissolution medium (Deaerated water) was placed in the vessel and temperature of 
medium was maintained at 37±0.5oC. The sample was placed in the medium and the 
dissolution was performed at 100rpm. 10 ml samples were withdrawn at 10, 20, 30, 
40……. .90 mins and equivalent amount of dissolution medium was added to maintain 
the sink condition. Samples were filtered (0.45 µm pore size) and analyzed by 
spectrophotometry at 270nm for HTC and 236nm for LSP. The experiments were 
carried out in triplicate and mean values and SD were recorded. 
Kinetic analysis of in-vitro release rates of solid dispersion of 
Hydrochlorothiazide and Losartan potassium  
The results of in-vitro release profile obtained for solid dispersion tablets were plotted 
in modes of data treatment as follows: 
1. Zero – order kinetic model - cumulative % drug released versus time. 
2. First  – order kinetic model – log cumulative %drug remaining versus time. 
a) Zero order kinetics 
 Zero order release would be predicted by following equation. 
At =A0 –K0t 
Where, 
                                       At  - Drug release at time ‘t’ 
A0  - Initial drug concentration 
K0  - Zero-order constant (hr-1) 
 When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys zero order kinetics, with a slope equal to K0. 
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b) First order kinetics: 
First order release would be predicted by the following equation: 
 
 
Where, 
 C = Amount of drug remained at time‘t’ 
 C = Initial amount of drug  
 K = First order rate constant (hr-1) 
 When the data plotted as Log cumulative percent drug remaining versus time 
yields a straight line, indicating that the release follow first order kinetics. The constant 
‘K’ can be obtained by multiplying 2.303 with slope values. 
7.3.5 In vivo Pharmacokinetic Study 
The pharmacokinetic study was performed on physical mixture, solid dispersion and 
commercial product, all in 1:4 ratio of HTC and LSP. 
Animals 
New Zealand white rabbits weighing 1.5 to 2.5kg were obtained from the 
animal house of Swamy Vivekananda College of Pharmacy. The animals were fed 
with cabbage and water. They were maintained in standard laboratory conditions 21±2 
0C and relative humidity of 55-60%. The animals were overnight fasted before the 
experiment. The study protocol was approved by the Institutional Animal Ethical 
Committee and the protocol number is SVCP/IAEC/M.Pharm/03/2011. 
Drugs 
Losartan potassium and Hydroclorothiazide pure  gift samples were obtained from 
Medrich Company Pvt. Ltd, Banglore, Karnataka, India. 
Chemicals 
Tragacanth from Loba Cheme Pvt Ltd, Mumbai. 
95% v/v alcohol 
 
                                             Log C0 –Kt 
LogC       =                               2.303 
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Requirements 
 Cotton 
 Surgical blade 
 26G needle 
 Blood collecting tubes (EDTA tubes)        
 Plasma sample collecting tubes (eppendrof’s tube) 
Sex: Both Male/Female 
No. of animals: 9 
Animal dose:  
Hydrochlorothiazide: Losartan potassium: 0.892: 3.5 mg/kg p.o (1:4ratio) 
Procedure for collection of blood:67 
  The animal was placed in a restrainer. Hair of the ear was shaved smoothly 
with blade without disturbing the blood vessels. Ear was cleaned with 95% v/v alcohol 
on the collection site and rapid rubbing on the ear to  dilate blood vessels which is easy 
to collect the blood. 2G needle was used to collect the blood from marginal ear vein. 
After collecting blood, clean sterile cotton was kept on the collection site and finger 
pressure was applied to stop the bleeding. Blood samples were placed in K3 EDTA 
tubes and centrifuged at 4000RPM for 30 min. Plasma was separated by using 
micropipette and placed in epindroff tubes. Separated plasma samples were stored  in 
refrigeration at -4ºc and analysed for HPLC.` 
 Experimental procedure: Rabbits were classified into 3 different groups each group 
consisting of 9 animals 
Group I Physical mixture (Hydrochlorothiazide: Losartan potassium) (1:4) P.o. 
Group II Solid dispersion (Hydrochlorothiazide: Losartan potassium) (1:4) P.o. 
Group III Commercial product (Hydrochlorothiazide: Losartan potassium) (1:4) P.o. 
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  Each group received Physical mixture or solid dispersion or commercial 
product suspended in distilled water using 1% tragacanth as a suspending agent. The 
suspension was administered P.o through an intragastric tube. Blood samples (1 ml) 
were collected in heparinized tubes from the marginal ear vein at 0, 0.5, 1, 1.5, 2, 4 and 
8 hrs after drug administration and plasma was separated by using centrifugation at 
4000 rpm and stored at -70°C. Samples were analysed by validated high performance 
liquid chromatography (HPLC).68 
 
Bioanalytical work 
HPLC chromatographic conditions  
            The HPLC system consisted of a Intersil C18 reversed phase analytical column 
(250mm × 4.6mm, 5µm) a shimadzu model SPD-6AV variable wavelength set as 
230nm . The mobile phase consisted of water with 2.5% formic acid, methanol and 
acetonitrile {40:45:15,v/v/v(%)}. The separation was performed under isocratic 
conditions with a constant flow rate of 0.7mL/min the injection volume was 10µL. 
Standard solutions and calibrators 68 
             Stock standard solutions of Losartan potassium (800µg/mL) and 
Hydrochlorothiazide (400 µg/mL) were freshly prepared in acetonitrile. A series of 
working standard solution were diluted in acetonitrile to produce eight standard 
solutions. The calibration standards were prepared by spiking 100µL of each standard 
solution to a final volume of 10mL plasma. 
 
Extraction of analytes from samples   
             To plasma aliquot (250µL) in an Eppendrof tube, a 0.5mL acetonitrile was 
added. The mixture was vortexted and centrifuged (4000rpm for 5min), 250µL aliquot 
of supernatant was transferred to a glass tube. The mixture was then evaporated to 
dryness. The residue was reconstituted with 1mL of water ; the mixture  was then 
vortexted , and a 10µL aliquot of the solution  was  injected into HPLC system. 
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Pharmacokinetic parameters 
 
 The pharmacokinetic parameters were calculated for each rabbit of Group I, Group II, 
Group III by the semi logarithmic plot of plasma Losartan potassium and 
Hydrochlorothiazide concentration at various intervals. The following pharmacokinetic 
parameters were calculated: 
 
1. Elimination rate constant (Ke): The elimination rate constant was determined 
using the formula 
Ke = -2.303 x slope of extrapolated curve 
 
2. Elimination half life (t1/2): t1/2 was calculated using the formula 
t1/2 = 0.693/Ke 
 
3. Absorption rate constant (Ka): This was determined by the method of 
residuals. The log linear portion of the decline phase was back extrapolated for each 
curve. The plasma concentration along this extrapolated line was C0. The observed 
plasma concentration C was subtracted from the corresponding extrapolated value at 
each time point. The semi logarithmic plot of residuals (C-C) against time yields a 
straight line. 
 
Ka = -2.303 x slope of residual line 
 
4. Absorption half life: It was calculated using the formula 
 
T1/2(a) = 0.693/Ka 
5. Apparent volume of distribution (Vd): It was calculated using the formula 
 
Vd =       Ka F X0 
                             (Ka - Ke) y intercept 
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6. Time to Cmax (tmax): tmax was calculated using the formula 
 
tmax =        ln Ka - ln Ke 
                Ka-Ke 
7. Maximum plasma concentration (Cmax): Cmax was calculated using the formula 
 
Cmax =    Y intercept (e-Ke. tmax – e-Ka. tmax) 
 
8. Area under curve (AUC0-12): AUC0-12 was calculated using the formula 
 
AUC   =       F X0 
                   Vd.Ke 
9. AUC0-∞ was calculated using the formula 
 
AUC0-∞ =     C0 
                   Ke 
 
STATISTICAL ANALYSIS: 
The values were expressed in mean ± SD and statistically analysed by one way 
ANOVA followed by Tukey-Kramer multiple comparison tests. 
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8. RESULTS 
COMPATIBILITY STUDY 
The FTIR spectra of pure drugs, physical mixture and solid dispersions of 
Hydrochlorothiazide and Losartan potassium are shown in Tables- 12,13 and Figures 
3-10. The spectra exhibited presence of characteristic peaks of drugs in physical 
mixture and indicate that there was no chemical interaction between the drugs. 
 
Table. 12 FTIR spectra of hydrochlorothiazide in physical mixtures and solid dispersion                                                                  
  
 
 
 
Characteristics Pure HCT F1 PM  F2 PM  F3 PM  F1 SD  F2 SD  F3 SD 
NH(Stretching) 3362.04-3173.01 
3362.04-
3174.94 
3362.04-
3178.79 
3360.97-
3182.65 3360.11 3358.18 3360.11 
NH (bending) 1602.90-1518.03 
1606.76-
1514 
1606.76-
1506.46 
1608.69-
1506.46- 
1599-
1516 
1600.97-
1516.10 
1600.97-
1506.46 
S=O(stretching) 1460.16 1460.16 1462.09 1462.09 1462.09 1462.09 1406.16 
Aromatic(CH-
Stretching) 2947.33 2955.04 2956.97 2956.97 2958.90 2956.97 2956.97 
Aromatic(CH-
Bending) 
858.35-
748.41 
842.92-
763.84 
840.99-
761.91 
840.99-
761.91 
817.85-
759.98 
821.70-
759.98 
879.57-
759.98 
C-Cl 
(Stretching) 
677.04-
607.60 
677.04-
607.60 
675.11-
609.53 
675.11-
609.53 675-603 
673.18-
605.67 
671.25-
605.67 
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Table.13 FTIR spectra of Losartan potassium in physical mixtures and solid dispersions 
                                                                      
 
 
 
 
 
 
 
Characteristics Pure LSP F1PM  F2 PM  F3 PM  F1 SD  F2 SD  F3 SD  
NH(Stretching) 
OH(Stretching 3194.23 3174.94 3178.79 3182.65 3219 3215.44 3223.16 
CH3-group CH 
bending 1425.44 1423.51 1425.44 1425.44 1425.44 1425.44 1423.51 
Halogen 
compounds, C-
Cl (Stretching) 
761.91 763.84 761.91 761.91 759.98 759.98 759.98 
OH primary 
alcohol, C-
N(Stretching) 
1259.56 1261.49 1259.56 1259.56 1255.71 1255.70 1255.70 
Aromatic ring, 
C-C multiple 
bond 
(Stretching) 
1575.89 1541.18 1575.89 1575.89 1562 1566.25 1575.97 
Aromatic 
hydrocarbon 
chromospheres, 
CH(Stretching) 
2956.97 2955.04 2956.97 2956.97 2958 2956.97 2956.97 
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Fig.3 FTIR SPECTRA OF PURE HYDROCHLORTHIAZIDE 
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Fig.4      FTIR SPECTRA OF PURE LOSARTAN POTASSIUM 
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Fig.5  FTIR SPECTRA OF HCT AND LSP (F1 S.D)   (1:2) 
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Fig.6 FTIR SPECTRA OF HCT AND LSP (F2S.D) (1:4) 
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Fig.7 FTIR SPECTRA OF HCT AND LSP (F3S.D)  (1:8) 
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Fig.8 FTIR SPECTRA OF HCT AND LSP ( F1P.M) (1:2) 
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Fig.9 FTIR SPECTRA  OF HCT AND LSP (F2P.M)  (1:4) 
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Fig.10 FTIR SPECTRA  OF HCT AND LSP (F3P.M) (1:8) 
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   DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
 
The DSC thermo gram of Hydrochlorothiazide, Losartan Potassium, P.Ms and 
S.Ds are shown in Tables 10-15 and Figures 11-18. A sharp endothermic peak at 
241.93°c and at 274.35°c was obtained for LSP and HCT respectively these peaks 
were corresponding to their melting point at their crystalline nature. In P.Ms the 
endothermic peak of HTC was shifted to lower melting temperature 226.53°c, 
237.23°c, and 243.42°c for F1 P.M, F2 P.M and F3 P.M respectively and the peaks 
were widened. Where as in S.Ds the endothermic peak of HTC was shifted to further 
low melting temperature 211.41°c, 229.53°c, and 229.57°c for F1 S.D,  F2 S.D, F3 S.D 
formulations respectively and the peaks of S.Ds were broader than those of P.M. LSP 
showed similar changes in both P.M and S.Ds in their thermogram. The endothermic 
peak of LSP was observed at 241.93°c was shifted to lower melting temperature 
161.75°c, 212.78°c, 185.65°c for F1 P.M, F2 P.M and F3 P.M formulations for S.Ds 
respectively and shifted to further lower melting temperature 141.43°c, 187.60°c and 
166.53°c for F1 S.D, F2 S.D, F3 S.D respectively and the endothermic peak in S.Ds 
were more broader than in P.Ms. The shifting and widening of endothermic peaks of 
HCT and LSP in both physical mixture and solid dispersions indicate change in solid 
state of the drug from crystalline to amorphous state. The endothermic peaks of HCT 
and LSP were broader in solid dispersions than observed in physical mixtures showing 
more amorphous state formulation in solid dispersions as compared to physical 
mixtures showing enhanced solubility of amorphous form of HCT.  
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Fig.12 
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Fig. 13 
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Fig.14 
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Fig.15 
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Fig.16 
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Fig.17 
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Fig.18 
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ESTIMATION OF DRUG CONTENT 
Both methods I and II produced linearity in the graph obtained by plotting 
concentration versus absorbance. There was no interference in the analysis of drugs. 
Table.14   Calibration curve data for Hydrochlorothiazide-Losartan Potassium       
absorbance in combination   
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Calibration Curve Of Losartan Potassium And 
Hydrochlorothiazide
LSP
HTC
 
s.no 
 
Concentration 0f 
drug (µg/mL) 
 
Absorbance of 
Hydrochlorothiazide at 270nm 
Absorbance of  
Losartan potassium at 
236nm 
1 0 0.003 0.001 
2 10 0.792 0.714 
3 20 1.634 1.37 
4 30 2.46 2.08 
5 40 3.16 2.67 
6 50 3.9 3.45 
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Table 15     Calibration data of Hydrochlorothiazide 
   
S.NO 
 
Concentration of 
Hydrochlorothiazide(µg/Ml) 
Absorbance at 270nm 
1 0 0 
2 1 0.0615 
3 2 0.135 
4 3 0.1863 
5 4 0.2475 
6 5 0.3102 
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PHASE SOLUBILITY STUDY 
             Phase solubility study was carried out in order to ascertain the effect of LSP 
on the solubility characteristics of HTC. The results are presented in Table -14 and 
Figure -19. Solubility of HTC was increased as the concentration of LSP increased. 
The solubility of HTC was minimal in deaerated water and increased approximately 
eight fold at 0.01% w/v of LSP in deaerated water. These data indicates that LSP in 
deaerated water acted as a new vehicle and solubility of HTC was greatly enhanced, 
possibly due to the solvent effect of LSP.    
Table:16 
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Fig.21
Effect of Losartan potassium on Solubility of 
Hydrochlorothiazide
S.No 
Concentration 
of Losartan 
Potassium 
(%w/v) 
Solubility of  
Hydrochlorothiazide 
in Losartan 
potassium solution 
(mg/ml) 
1 0 0.2123 
2 0.0025 0.3610 
3 0.0050 0.5270 
4 0.010 1.6535 
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 In-vitro dissolution studies 
The data of the In vitro dissolution studies as cumulative % drug release Vs 
time performed on P.Ms, S.Ds and C.P on deaerated water are shown in Tables 17-26 
and figures 22-45. There were differences in dissolution pattern of HTC between P.M 
1, P.M 2 and P.M 3 formulations. The % drug dissolved at every time point intervals 
was statistically analyzed and it was observed at 10 min. The % drug dissolved from 
P.Ms was found to increase as the concentration of LSP is increased and all the P.M s 
showed about 90% release of HTC in 80min. When compared with pure HTC P.Ms 
showed faster dissolution while pure HTC dissolved 90% at 150 min the P.M 
dissolved 90% HTC in 80min. Thus showing faster dissolution of HTC from P.Ms as 
compared to pure HTC. Though there was a significant difference in dissolution 
pattern of HTC from P.Ms at different time intervals, no significant difference was 
observed in dissolution pattern all P.Ms at 80 min, at which fine point 90% dissolution 
of HTC was observed. Since LSP is freely soluble in dissolution media a uniform 
dissolution pattern of this drug was observed from P.Ms. S.Ds showed similar 
dissolution pattern as observed with P.Ms at different time point intervals and there 
were significant differences in percent (HTC) drug dissolved between different time 
point intervals. However S.Ds showed faster dissolution of HTC as compared to P.Ms. 
90% dissolution of HTC was at shorter time (50min) from S.D3 formulation as 
compared to S.D1, S.D2 formulations which showed 90% dissolution of HTC at longer 
time (70min). These finding suggests that S.Ds showed faster dissolution rate of HTC 
as compared to P.M or pure drug. The enhanced dissolution of HTC from P.Ms is due 
to the solvent effect of LSP. The magnitude of dissolution was significantly higher 
from S.Ds as compared to P.Ms the mechanisms for improved dissolution of HTC 
from S.D is due to firstly, the solvent effect of LSP on the solubility of HTC; Secondly 
the change of physical state of HTC from crystallinity to amorphous state as seen in 
DSC thermogram and thirdly possible micronization of poorly soluble HTC, reduced 
particle size, larger surface area and so enhanced dissolution of the drug in the 
environment. The dissolution pattern of LSP whether from P.M or from S.D assumes 
no significance in the study as the drug is freely soluble. 
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Table 17   In-Vitro Dissolution Profile of Pure Hydrochlorothiazide in deaerated 
water 
Time(min) Trial 1 Trial 2 Trial 3 Mean cumulative %drug 
release 
0 0 0 0 0 
10 3.17 3.21 4.50 3.62  ± 0.756 
20 9.15 8.97 9.12 9.08  ± 0.096 
30 16.42 17.51 17.14 17.11 ± 0.6025 
40 19.25 19.27 19.25 19.31 ±  0.092 
50 24.19 25.12 24.11 24.47 ±  0.5615 
60 34.45 33.21 34.36 34.00  ± 0.6914 
70 45.15 44.17 44.84 44.72 ±  0.5009 
80 53.7 54.73 54.30 54.24 ± 0.5173 
90 59.9 60.1 60.2 60.06 ± 0.1528 
100 65.2 66.24 66.1 65.84 ± 0.5644 
110 67.42 68.43 67.2 67.68 ±0.655 
120 72.81 72.92 73.32 73.01 ± 0.268 
130 76.32 75.92 77.1 76.44 ±0.6001 
140 85.12 84.89 85.3 85.103±  0.2055 
150 92.13 92.15 93.16 92.48 ± 0.5890 
160 96.62 95.92 96.53 96.3566 ± 0.3808 
170 98.13 98.14 98.23 98.16 ± 0.055 
180 98.39 99.2 99.62 99.07 ± 0.6252 
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Table 18   In-vitro Dissolution Profile for Physical Mixture F1 in deaerated water 
Hydrochlorothiazide Losartan Potassium 
Time 
(min) 
Trial   
1 
Trial 
2 
Trial 
3 Mean ± SD 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 22.34 22.89 21.89 22.55±0.2972 80.71 78.91 80.68 80.01±1.031 
20 41.91 41.70 41.15 41.586±0.3925 83.23 84.15 82.73 83.37±0.7203 
30 62.28 63.19 60.99 62.1533±1.105 85.91 85.00 86.05 85.65±0.5701 
40 70.64 69.43 70.43 70.16±0.6466 87.52 86.53 87.98 87.34±0.7401 
50 77.93 75.32 77.83 77.026±1.479 90.23 91.13 88.37 89.91±1.408 
60 81.54 80.48 81.63 81.216±0.639 91.03 92.24 92.48 91.916±0.77 
70 88.59 88.62 87.48 88.23±0.6497 92.32 93.78 93.49 93.19±0.77 
80 92.61 92.52 91.70 92.27±0.5014 95.18 94.79 95.39 95.12±0.3083 
90 95.46 94.52 96.45 95.476±0.9651 96.47 95.68 97.66 96.60±1.9967 
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Release kinetics of HCT from F1 P.M in deaerated water 
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Table 19   In-vitro Dissolution Profile for physical mixture F2 in deaerated water 
 
     
 
 
 
 
 
Hydrochlorothiazide Losartan Potassium 
Time 
(mins) 
Trial 
1 Trial 2 Trial 3 Mean ± SD Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 19.88 19.18 20.23 19.76±0.5328 80.18 79.87 80.03 80.03±0.1527 
20 37.01 36.30 37.35 36.89±0.5335 84.39 84.09 82.56 83.68±0.9819 
30 65.30 64.61 65.65 65.19±0.5341 88.01 87.69 87.84 87.84±0.1530 
40 71.31 70.61 72.36 71.42±0.8797 92.22 91.91 92.06 92.07±0.1532 
50 78.71 78.01 79.07 78.60±0.5356 93.85 93.54 92.47 93.29±0.7229 
60 84.38 83.68 85.08 84.38±0.7011 95.02 94.72 93.49 94.41±0.8101 
70 88.66 87.96 89.37 88.66±0.7018 95.89 95.58 94.97 95.48±0.4695 
80 93.65 92.94 94.01 93.53±0.5377 96.76 96.45 95.84 96.35±0.4700 
90 95.15 94.44 97.24 95.61±1.4577 97.33 97.02 96.71 97.02±0.3093 
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Release kinetics of HCT from F1 P.M in deaerated water 
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Table .20   In-vitro dissolution profile for physical mixture F3 in deaerated water 
 
               
 
 
 
 
 
 
 
 
 
Hydrochlorothiazide Losartan Potassium 
Time 
(min) 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD Trial 1 Trial 2 Trial 3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 26.0 26.57 27.15 26.57±0.5778 80.33 84.17 84.34 82.95±2.2675 
20 45.09 45.67 46.25 45.67±0.5784 88.77 89.11 89.27 89.05±0.2555 
30 66.52 67.10 67.68 67.10±0.5790 91.38 92.05 93.72 92.38±1.2049 
40 72.95 73.53 74.11 73.53±0.5797 94.99 95.32 96.16 95.49±0.6041 
50 79.39 79.97 80.55 79.97±0.5803 96.09 96.43 96.77 96.43±0.3366 
60 82.94 83.52 84.10 83.52±0.5810 97.03 97.20 97.71 97.31±0.3506 
70 87.08 88.24 88.82 88.04±0.8863 97.48 98.15 98.32 97.98±0.4448 
80 92.37 94.11 94.69 93.73±1.2074 97.92 98.59 98.59 98.37±0.3888 
90 96.52 98.26 98.27 97.68±1.0063 98.69 99.03 98.87 98.86±0.1690 
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Release kinetics of HCT from F3 P.M in deaerated water 
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Table 21   In-vitro dissolution profile for solid dispersion F1 in deaerated water 
  
Hydrochlorothiazide Losartan Potassium 
Time 
(mins) 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 26.01 24.15 26.01 25.39±1.0774 81.80 77.71 79.76 79.75±2.0425 
20 45.55 43.69 44.62 44.62±0.9300 83.94 79.84 81.89 81.89±2.0474 
30 65.11 63.24 64.17 64.17±0.9317 88.94 88.52 88.73 88.73±0.2090 
40 73.54 71.68 72.61 72.61±0.9320 90.67 90.26 90.46 90.46±0.2092 
50 82.91 81.05 81.98 81.98±0.9331 93.64 93.22 93.43 93.43±0.2095 
60 90.44 88.57 89.50 89.50±0.9341 94.56 94.14 94.35 94.35±0.2097 
70 93.32 91.45 92.39 92.39±0.9352 95.69 95.27 95.48 95.48±0.2099 
80 95.28 93.41 94.35 94.35±0.9362 96.61 96.19 96.40 96.40±0.2101 
90 96.32 94.44 95.38 95.38±0.9372 97.34 96.94 97.29 97.19±0.2213 
  
              
 
 
 
 
 
 
 
 
 
  
 
 
 
72 
 
                Release kinetics of HCT from F1 S.D in deaerated water 
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Table 22   In-vitro dissolution profile for solid dispersion F2 in deaerated water 
Hydrochlorothiazide Losartan Potassium 
Time 
(mins) 
Trial 1 Trial 2 
Trial 
3 Mean ± SD 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 20.29 19.55 19.92 19.92±0.3687 83.31 83.00 83.15 83.15±0.1539 
20 38.76 38.02 38.39 38.39±0.3694 84.78 84.48 84.63 84.63±0.1541 
30 74.97 74.23 74.60 74.60±0.3698 89.96 89.65 89.81 89.81±0.1543 
40 81.33 80.58 80.96 80.96±0.3702 91.91 91.60 91.75 91.75±0.1545 
50 87.69 86.95 87.32 87.32±0.3706 94.01 93.70 93.86 93.86±0.1546 
60 88.89 88.15 88.52 88.52±0.3710 96.89 96.58 96.73 96.73±0.1548 
70 91.21 90.46 90.83 90.83±0.3714 97.31 96.99 97.15 97.15±0.1550 
80 95.73 94.99 95.36 95.36±0.3718 97.72 97.41 97.56 97.56±0.1551 
90 96.95 96.20 96.57 96.57±0.3722 98.60 98.29 98.44 98.44±0.1553 
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Release kinetics of HCT from F2 S.D in Deaerated water 
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%Drug release of HCT from F2 S.D
y = 1.034x + 20.67
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Zero order plot of HCT from F2 S.D
y = -0.016x + 1.615
R² = 0.902
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First order plot of HCT from F2 S.D
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Table 23   In-vitro dissolution profile for solid dispersion F3 in deaerated water 
  
Hydrochlorothiazide Losartan Potassium 
Time 
(mins) 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 35.17 33.96 35.78 34.97±0.9264 86.70 86.37 86.87 86.65±0.2522 
20 60.04 58.82 60.64 59.84±0.9264 89.61 89.28 89.77 89.55±0.2525 
30 73.38 72.17 73.99 73.18±0.9264 93.01 92.68 93.17 92.95±0.2528 
40 82.48 81.26 83.08 82.28±0.9264 96.08 95.75 96.25 96.03±0.2531 
50 90.97 89.76 91.57 90.77±0.9264 97.68 97.35 97.84 97.62±0.2534 
60 94.01 92.79 94.61 93.80±0.9264 97.95 97.62 98.12 97.90±0.2536 
70 96.43 95.21 97.03 96.22±0.9264 98.39 98.06 98.56 98.33±0.2539 
80 97.59 95.82 97.64 97.02±1.0352 98.83 98.50 99.00 98.77±0.2542 
90 98.25 97.03 98.85 98.04±0.9264 99.27 98.93 99.43 99.21±0.2545 
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Release kinetics of HCT from F3 S.D in deaerated water 
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% Drug release of HCT from F3 S.D
y = 0.950x + 29.82
R² = 0.783
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Zero order plot of HCT from F3 S.D
y = -0.019x + 1.521
R² = 0.891
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First order plotof HCT from F3 S.D
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Table-24   In-Vitro dissolution profile for F2 commercial product  in deaerated 
water 
Hydrochlorothiazide Losartan Potassium 
Time 
(mins) 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
Trial 
1 
Trial 
2 
Trial 
3 Mean ± SD 
0 0 0 0 0 0 0 0 0 
10 21.72 23.32 21.73 22.25±0.92 75.75 73.75 75.23 74.91±1.03 
20 31.73 30.54 32.73 31.66±1.09 82.49 80.95 83.49 82.31±1.28 
30 45.19 44.82 44.28 44.76±0.45 88.97 86.22 88.97 88.05±1.58 
40 54.89 63.25 62.19 60.11±4.55 90.12 90.47 93.91 91.5±2.09 
50 72.97 71.96 72.86 72.59±0.55 94.41 91.10 94.44 93.31±1.92 
60 74.79 76.00 73.69 74.82±1.15 95.73 94.71 92.74 94.39±1.52 
70 80.48 80.77 81.02 80.75±0.27 96.24 96.33 95.68 96.08±0.35 
80 83.88 83.25 82.81 83.31±0.53 98.12 98.89 98.56 98.52±0.38 
90 85.81 87.29 85.81 86.30±0.55 99.02 99.66 100.15 99.61±0.56 
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Release kinetics of HCT from F2 C.P in deaerated water 
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%Drug release of HCT from F2 C.P
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Zero order plot of HCT from F2 C.P
y = -0.940x + 86.67
R² = 0.922
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First order plot HCT from F2 C.P
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   Table 25    Release kinetics of Physical Mixtures 
 
 
 
 
 
 
 
 
 
Formulation 
code 
HYDROCHLOROTHIAZIDE 
F1 PM F2 PM F3 PM 
Zero order 
“R2”value 
 
 
0.891 
 
0.880 
 
0.866 
 
First order 
“R2”value 
 
0.921 
 
0.982 
 
0.990 
 
Best fit model 
 
First order 
 
First order 
 
First order 
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Table:26 Release kinetics of  Solid Dispersions 
 
 
 
  
Formulation code 
HYDROCHLOROTHIAZIDE 
F1 SD F2 SD F3 SD 
Zero order 
“R2”value 
 
 
0.869 
 
0.810 
 
0.783 
 
First order 
“R2”value 
 
0.976 
 
0.902 
 
0.891 
 
Best fit model 
 
First order 
 
First Order 
 
First order 
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COMPARATIVE DISSOLUTION OF PHYSICAL MIXTURES AND SOLID 
DISPERSIONS IN DEAERATED WATER 
 
Table 27  Physical mixtures 
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Comparitive drug release of physical mixtures
PM 1 HTZ
PM 1 LSP
PM 2 HTZ
PM 2 LSP
PM 3 HTZ
PM 3 LSP
Time 
(mins) 
PM1 PM2 PM3 
HCTZ LSP HCTZ LSP HCTZ LSP 
0 0  0 0 0 0 0 
10 22.55 80.01 22.13 80.03 26.57 82.95055 
20 41.589 83.37 41.22 83.68 45.67 89.05647 
30 62.1533 85.65 61.94 87.84 67.10 92.38427 
40 70.16 87.34 70.19 92.07 73.53 95.49296 
50 77.026 89.91 76.80 93.29 79.97 96.43381 
60 81.216 91.916 81.20 94.41 83.52 97.31992 
70 88.23 93.19 87.71 95.48 88.04 97.9842 
80 92.27 95.12 91.97 96.35 93.73 98.37075 
90 95.476 96.60 94.54 97.02 97.68 98.86895 
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Table 28        comparative dissolution profile of solid dispersions 
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Fig:45
Comparative drug release of solid dispersions
SD 1 HTC
SD1 LSP
SD 2 HTC
SD 2 LSP
SD 3 HTC
SD 3 LSP
Time 
(mins) 
SD1 SD2 SD3 
HCTZ LSP HCTZ LSP HCTZ LSP 
0 0 0 0 0 0 0 
10 19.92618 79.75968 25.39329 83.15735 34.97422 86.65235 
20 38.39881 81.89524 44.62096 84.6357 59.8403 89.55629 
30 74.60408 88.73518 64.17998 89.81148 73.18306 92.95883 
40 80.96001 90.46971 72.61241 91.759 82.2804 96.03473 
50 87.32291 93.43316 81.98315 93.86258 90.77125 97.62751 
60 88.52669 94.35462 89.50617 96.73835 93.80371 97.9007 
70 90.83872 95.4815 92.39234 97.15328 96.22965 98.33922 
80 95.36725 96.40501 94.35257 97.56855 97.02034 98.77811 
90 96.57964 97.19419 95.38585 98.44616 98.04913 99.21736 
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IN-VIVO PHARMACOKINETIC STUDY 
            Pharmacokinetics of C.P, P.M and S.D are presented in Tables 26-29 and 
Figures. The Ka, KE, Cmax, Vd, AUC0-8 of HCT were significantly increased (p< 0.05) 
from solid dispersion as compared to P.M or C.P and these increases are as result of 
enhanced dissolution and absorption of HCT brought about by change of crystallinity 
to amorphous form and reduced particle size of HCT in solid dispersion. The 
pharmacokinetics of commercial product did not show significant difference with 
physical mixtures. The values of Tmax and t1/2 of HCT in solid dispersion decreased and 
this decrease was significant as compared to P.M or C.P (p<0.05). As Ka of HCT from 
solid dispersion was significantly increased, the Tmax and  t1/2  values was decreased. 
These findings clearly suggest that the pharmacokinetics of HCT from solid dispersion 
was better than that of P.M and C.P.             
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Hplc Chromatographs of C.P, P.M and S.D 
                                    Commercial Product 
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Physical Mixture 
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Solid Dispersion 
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Table.29 COMMERCIAL PRODUCT 
 
 
 
 
 
 
 
Table.30 PHYSICAL MIXTURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.N
O 
Parameter     Animals (n=3)  
Mean± S.D 
 
S.E.M 
        
1  
     
    2 
      
 3 
   1 Ke (hr-1)   0.14 0.19 0.2 0.17±  0.032 0.018 
   2 Ka  (hr-1) 0.5 0.3 0.8 0.53 ±  0.25 0.14 
   3 t 1/2   3.01 3.46 3.3 3.35±  0.2 0.13 
   4 
 Vd      2.69 2.36 2.48 2.51±  0.16 0.096 
   5  Cmax 1.11 1.09 1.13 1.11±  0.02 0.011 
   6 Tmax 6.2 6.89 6.32 6.47±  0.36 0.212 
   7 AUC0-8 2.7 2.63 2.82 2.71±  0.09 0.55 
 
S.N
O 
Parameter     Animals (n=3)  
Mean± S.D 
 
S.E.M 
        
1  
     
    2 
      
 3 
   1 Ke (hr-1)   0.14 0.13 0.15 0.14±  0.010 0.005 
   2 Ka  (hr-1) 0.32 0.36 0.34 0.34±  0.020 0.011 
   3 t 1/2   3.56 3.2 3.5 3.42±  0.19 0.11 
   4 
 Vd      1.99 2.0 2.2 2.063±  0.11 0.068 
   5  Cmax 0.12 0.11 0.22 0.15±  0.06 0.0351 
   6 Tmax 7.69 7.83 7.62 7.71±  0.106 0.061 
   7 AUC0-8 2.79 2.2 2.4 2.46±  0.30 0.173 
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Table.31 SOLID DISPERSION 
 
 
 
 
 
  
 
 
 
                                                                         
Table.32 COMPARITIVE STUDY OF PHARMACOKINETIC PARAMETERS 
 
 
 
 
 
 
 
 
S.N
O 
Parameter Animals (n=3)  
Mean± S.D 
 
S.E.M 1  
2 
 
3 
1 Ke (hr-1) 0.23 0.2 0.21 0.21±  0.015 0.008 
2 Ka  (hr-1) 1.84 1.82 1.81 1.82±  0.015 0.008 
3 t  1/2 2.1 2.3 2.6 2.33±  0.25 0.145 
4 Vd 4.80 4.49 4.62 4.63±  0.155 0.089 
5 Cmax 1.4 1.2 1.30 1.3±  0.1 0.057 
6 Tmax 5.2 5.6 5.3 5.36±  0.20 0.120 
7 AUC0-8 4.4 4.2 3.18 3.92±  0.65 0.37 
 
S.NO 
 
Parameter 
                          Mean ± S.D P VALUE 
 of  S.D C.P P.M S.D 
   1 Ke (hr-1)   0.17±  0.032 0.14±  0.010 0.21±  0.015 P<0.05 
   2 Ka  (hr-1) 0.53 ±  0.25 0.34±  0.020 1.82±  0.015 P<0.001 
   3 t  1/2   3.35±  0.2 3.42±  0.19 2.33±  0.25 P<0.01 
   4 Vd      2.51±  0.16 2.063±  0.11 4.63±  0.155 P<0.001 
   5  Cmax 1.11±  0.02 0.15±  0.06 1.3±  0.1 P<0.001 
   6 Tmax 6.47±  0.36 7.71±  0.106 5.36±  0.20 P<0.01 
   7 AUC0-8 2.71±  0.09 2.46±  0.30 3.92±  0.65 P<0.05 
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Ke (hr-1) of Commercial product, Physical mixture and Solid Dispersion. 
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Tmax of Commercial Product, Physical Mixture and Solid Dispersion 
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Vd of Commercial Product, Physical Mixture and Solid Dispersion 
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AUC0-8 of Commercial Product, Physical Mixture and Solid Dispersion 
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9. DISCUSSION 
The results of the present study demonstrate that a novel drug-drug solid 
dispersion approach can improve dissolution and pharmacokinetic characteristics of 
the poorly soluble drug that was presented with the soluble drug in fixed dose 
formulation. This novel approach will obviate the need for inclusion of physiological 
water soluble inert carriers in solid dispersion and so cost effective. Besides, this 
approach stabilizes the formulation from the effect of moisture that is normally 
encountered in solid dispersions prepared with physiological inert carriers.  
In the present study HTC-LSP, the FDC used in the treatment of hypertension 
was selected as a model for this novel drug–drug solid dispersion approach and its 
physiochemical, in vitro release and pharmacokinetic characteristics were investigated. 
HTC though rapidly absorbed from the GIT following oral administration, its poor 
solubility may pose dissolution rate limited absorption problem. The in vitro release of 
solid dispersion has shown enhanced dissolution of HCT as compared to physical 
mixture or commercial product. 
The HCT which was present in crystalline form in physical mixture was 
changed to amorphous form in the solid dispersion as evident from DSC thermogram. 
The amorphous form of HCT was more soluble than its crystalline form and so an 
improved dissolution of HCT was observed from solid dispersion. Additionally LSP 
which is freely soluble has increased the solubility of HCT due to its solvent effect as 
shown in phase solubility study. 
To substantiate the effect of these changes in solid dispersion on the 
pharmacodynamic of HCT, a study was carried out in rats in our laboratory and it has 
observed that the improved solubility and dissolution of HCT in solid dispersion 
showed positive correlation with improved diuretic effect of HCT (unpublished data). 
These findings tempted to investigate further the pharmacokinetics of the solid 
dispersion in comparision with P.M and C.P. The solid dispersion has shown an 
improved pharmacokinetics of HCT which was significantly higher than that of P.M 
and C.P. 
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10. SUMMARY AND CONCLUSION 
 
 The present study shows improved dissolution and pharmacokinetics of HCT   
            from a modified novel drug-drug solid dispersion. 
 Dissolution and pharmacokinetics of HCT was better from HCT-LSP solid  
            dispersion as compared to physical mixture and commercial product. 
 This novel solid dispersion is stable as no physiological inert carriers that are  
            affected by moisture are used. 
 Cost effective and economical as this approach is free of the economical   
            burden of physiological inert carriers. 
 Further studies in humans are recommended to address the therapeutic  
            advantages of the novel solid dispersion in clinical practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
100 
 
11.REFERENCES 
 
1. Wadke, D. A.; Serajuddin, A. T. M.; Jacobson, H. Preformulation testing. In  
            Pharmaceutical Dosage Forms: Tablets,Lieberman, H. A; Lachman, L;  
            Schwartz, JB.Eds.;Marcel Dekker: New York, 1989;1; 1-73. 
 
2. Atkinson R.M, Bedford C., Child K. J, and Tomich E. G,  
            Antibiot.Chemother., 1962 12,232. 
 
3. Levy G, Lancet 1962, 2,723. 
 
4. Bauer.G, Rieckmann.P, and Schaumann. W, Arzneim.-Forsch., 1962, 12,487. 
 
5. Ahuja.N, Katare.O.P, Singh.B . Studies on dissolution enhancement and  
             mathematical modeling of drug release of a poorly water-soluble drug using  
           water-soluble carriers. Eur J Pharm Biopharm 2007; 65, 26-38. 
 
6. Amidon.G.L, Lennernäs.H, Shah.V.P, Crison.J.R. A theoretical basis for a  
             biopharmaceutic drug classification: the correlation of in vitro drug product  
           dissolution and in vivo bioavailability. Pharm Res 1995; 12:413-420. 
 
7. Sekiguchi.K, Obi.N. Studies on absorption of eutectic mixture. I. A  
            comparison  of the behavior of eutectic mixture of sulfathiazole and that of  
            ordinary sulfathiazole in man.Chem. Pharm. Bul. 1961, 9, 866-872. 
 
8. Chiou, W. L, Riegelman, S. Pharmaceutical applications of solid dispersion  
            systems. J. Pharm. Sci. 1971, 60, 1281-1302. 
 
9. Goldberg.A.H.; Gibaldi.M., Kanig.J.L. Increasing dissolution rates and  
              gastrointestinal absorption of drugs via solid solutions and eutectic mixtures  
              II. Experimental evaluation of eutectic mixture: urea-acetaminophen system.  
            J. Pharm.Sci. 1966, 55, 482-487. 
  
 
 
 
101 
 
10. Goldberg, A. H.; Gibaldi, M.; Kanig, J. L. Increasing dissolution rates and       
              gastrointestinal absorption of drugs via solid solutions and eutectic mixtures  
II Experimental evaluation of griseofulvin-succinic acid solution. J. Pharm.  
Sci. 1966, 55, 487-492.  
 
11. Mayersohn and Gibaldi M., J. Pharm. Sci., 1966, 55, 1323.  
 
12. Sica, Domenic. Drugs, 2002, Volume 62,3, 443-462. 
 
13. Joel G. Hardman et al. Goodman and Gilman’s pharmacological basis of  
            therapeutics; 1985, 743-45,. 
 
14. Lakshmi Narasaiah.V, Kalyan Reddy. B, Raj Kumar. M, Kiran Kumar, J.  
            Chem. Pharm.Res., 2010, 2, 304-331. 
 
15. James K; “Solubility and related properties”, Marcel Dekker, Newyork, 28  
            986, 127 –146, 355 – 395. 
  
16. Indian Pharmacopoeia, Ministry of Health and family welfare, Government of  
            India, Published by the controller of publications, Delhi, 1996, 1, 7.  
 
17. Saharan et al. Dissolution Enhancement of Drugs Int J Health Res, June 2009;  
            2 (2): 1 05 
 
 
18. Aggarwal S, Gupta GD and Chaudhary S. Solid dispersion as an eminent  
            strategic approach in solubility enhancement of poorly soluble drugs.  
              International Journal of Pharmaceutical Sciences and Research, 2010, 1, 1-13. 
 
19. Mohanachandran PS, Sindhumo PG and Kiran TS. Enhancement of solubility          
            and dissolution rate: an overview. International Journal of Comprehensive  
  
 
 
 
102 
 
            Pharmacy, 2010, 4, 1-10. 
20. Chawdhary KPR, Vijayasrinivas S. Biopharmaceutical classification system.  
            Indian Pharmacist 2004; 7-10. 
 
21. Sharma D, Soni M, Kumar S and Gupta G.D. Solubility Enhancement – 
            Eminent Role in Poorly Soluble Drugs. Research Journal of Pharmacy and  
            Technology, 2009, 2, 220-224. 
 
22. Pinnamaneni S, Das N.G, Das S.K; Formulation approaches for orally  
            administered poorly soluble drugs. Pharmazie, 2002; 57: 291 – 300.  
 
23. Arora S.C, Sharma P.K et al. Development, characterization and solubility  
             study of solid dispersion of cefixime trihydrate by solvent evaporation method.  
           International Journal of Drug Development & Research, 2010, 2,424-430. 
 
24. Ahire B.R, Rane B.R, Bakliwal SR and Pawar SP. Solubility Enhancement of  
            Poorly Water Soluble Drug by Solid Dispersion Techniques. International  
            Journal of Pharm tech Research, 2010, 2, 2007-2015. 
 
25. ChaudhariP.D et al. Current trends in solid dispersions techniques.  
            pharmainfo.net, 2006, 4. 
 
 
26. Arunachalam A, Karthikeyan M. et al. Solid Dispersions: A Review. Current  
            Pharma Research, 2010, 1, 82-90. 
 
27. Craig D.Q.M. The mechanisms of drug release from solid dispersions in  
             water-soluble polymers. International Journal of Pharmaceutics, 2002,   
             231,131-144. 
 
28. Khan M.S.A. Solid dispersions: Formulation, characterisation, permeability  
            and genomic evaluation [dissertation]. Aston University, 2010, 40-42. 
  
 
 
 
103 
 
29. Ghaste .R, Dhanyakumar D.C, Shah R.R, and Ghodke D.S. Solid dispersion:  
            an overview. Pharmainfo.net, 2009, 7. 
30. Aruna Rawat, Surrender Verma, Mahima Kaul and Sapna Saini. International  
             journal of pharmacy and technology, 2011, 3, 1062-1099. 
 
31. Aleem M.A. Solid Dispersion – an Approach to Enhance the Dissolution rate  
             of Aceclofenac [dissertation]. Karnataka, Bangalore, Rajiv Gandhi University  
           of Health Science, 2006, 15. 
 
32. Van den Mooter .G, Weuts I, Ridder T.D, Blaton N. Evaluation of Inutec SP1  
             as a new carrier in the formulation of solid dispersions for poorly soluble  
            drugs. Int J Pharm. 2006; 316:1–6.  
 
33. Chauhan.B, Shimpi.S, Paradkar.A. Preparation and evaluation of  
              glibenclamide polyglycolized glycerides solid dispersions with silicon dioxide  
            by spray drying technique. Eur J Pharm Sci. 2005; 26:219–230.  
 
34. Vasanthavada M, Tong W.Q, Joshi Y, Kislalioglu, M.S. Phase behavior of  
            amorphous molecular dispersions I: Determination of the degree and  
            mechanism  of solid solubility. Pharm Res. 2004; 21:1598–1606.  
 
35. Johari G.P, Kim S, Shankar, R. Dielectric studies of molecular motions in  
             amorphous solid and ultraviscous acetaminophen. J Pharm Sci. 2005;  
             94:2207–2223.  
 
36. Tiwari R, Tiwari G, Srivastava B and Rai A.K. Solid Dispersions: An  
            Overview to Modify Bioavailability of Poorly Water Soluble Drugs.  
             International Journal of Pharm tech Research, 2009, 1, 1338-1349. 
37. Chiou, W.L.; Riegelman.S. Preparation and dissolution characteristics of  
              several fast-release solid dispersions of griseofulvin. J. Pharm. Sci. 1969, 58,  
            1505-1509. 
38. Simonelli, A. P.; Mehta, S. C.; Higuchi, W. I. Dissolution rates of high energy  
  
 
 
 
104 
 
              poly(vinylpyrrolidone)(PVP)-sulfathiazole coprecipitates. J. Pharm. Sci. 1969,  
            58, 538-549. 
39. Thakkar A.L.; Hirsch C.A, Solid dispersion approach for overcoming  
             bioavailability problems due to polymorphism of nabilone, a cannabinoid  
             derivative. J. Pharm. Pharmacol. 1977, 29, 783-784. 
 
40. Usui.F, Maeda.K, Kusai.A.; Ikeda,M., Nishimura.K, Yamamoto.K.  
              Dissolution improvement of RS-8359 by the solid dispersion prepared by the  
           solvent method. Int. J. Pharm. 1998, 170, 247-256. 
 
41. Vera, N.; Veiga, M. D.; Cadorniga, R. Solid dispersions of oxodipine/PEG  
             6000 characterization and dissolution study. S. T. P. Pharma Sci. 1991, 1,    
             125-129. 
 
42. Fernandez.M , Rodriguez, I.C, Margarit, M.V, Cerezo, A. Characterization of   
             solid dispersions of piroxicam/poly-(ethylene glycol) 4000. Int. J. Pharm.  
           1992, 84, 197-202. 
 
 
43. Singla.A.K , Vijan.T. Dissolution of sulfamethoxazole from poly(ethylene  
             glycol) and poly(vinylpyrrolidone) solid dispersions. Drug Dev. Ind. Pharm.  
          1990, 16, 875-882. 
 
44. Corrigan.O.I, Holohan.E.M. Amorphous spray-dried hydroflumethiazide  
             poly(vinylpyrrolidone) systems: physicochemical properties. J. Pharm.  
             Pharmacol. 1984, 36, 217-221. 
 
45. Takahashi.Y, Tsukuda.T, Izumi.C, Ikemoto.K, Kokubun.K, Yagi.N,  
            Takada.M. Preparation of solid dispersion systems of disopyramide with  
             poly(vinylpyrrolidone) and ç-cyclodextrin. Chem. Pharm. Bull. 1988, 36,  
             2708-2710. 
46. Jachowicz, R.; Nurnberg, E, Hoppe, R. Solid dispersions of oxazepam. Int. J.  
  
 
 
 
105 
 
            Pharm. 1993, 99, 321-325. 
 
47. Kai.T, Akiyama.Y, Nomura.S, Sato.M. Oral absorption improvement of  
             poorly soluble drug using solid dispersion technique. Chem. Pharm. Bull.   
             1996, 44, 568-571. 
 
48. Ho.H.O, Shu.H.L, Tsai.T, Sheu.M.T. The preparation and characterization of  
              solid dispersions on pellets using a fluidized bed system. Int. J. Pharm. 1996,  
            139, 223-229. 
 
49.      Betageri.G.V, Makarla.K.R. Enhancement of dissolution of glyburide by solid  
              dispersion and lyophilization techniques. Int. J. Pharm. 1995, 126, 155-160. 
 
50. Abd el-Fattah .S, Boraie N.A, Hassan H.M, Enhancement of dissolution rate  
             of hydrochlorothiazide via solid dispersion. Pharmazie. 1986 Nov; 41(11):790- 
            3. 
 
51. Panayotis E, Macheras, Michael A, Koupparis and Sophia G, Antimisiaris  
            Pharmaceutical Research, 1990, 7, 5. 
 
52. Millar F.C and Corrigan O.I.  Influence of Sodium Caseinate on the Dissolution  
          Rate of Hydrochlorothiazide and Chlorothiazide, 1991, 17, 1593-1607. 
 
53. Sam Corveleyn, Jean Paul Remon. Formulation and production of rapidly  
              disintegrating tablets by lyophilisation using hydrochlorothiazide as a model  
            drug. International Journal of Pharmaceutics. 1997,152, 215–225. 
54. Chris Vervaet and Jean Paul Remon. Bioavailability of Hydrochlorothiazide  
            from pellets, made by extrusion containing polyetheleneglycol 400 as an  
           dissolution enhancer. 1997, pharmaceutical research, 14. 
 
55. Randy L. Webb, Aida E. Navarrete, and Scott Davis. Effects of Valsartan and  
             Hydrochlorothiazide Alone and in Combination on Blood Pressure and Heart  
  
 
 
 
106 
 
           Rate in Conscious-Telemetered Spontaneously Hypertensive Rats (SHR).  
           American jounal of Hypertension. 1998, 11, 60. 
 
56. Paraskevi Kallinteri, Sophia G. Antimisiaris. Solubility of drugs in the  
            presence of gelatin: effect of drug lipophilicity and degree of ionization.  
            International Journal of Pharmaceutics, 2001, 221, 219–226. 
 
57. Ndindayino.F, Vervaet .G. Van den Mooter J.P. Remon. Direct compression  
              and moulding properties of co-extruded isomalt/drug mixtures. International  
            Journal of Pharmaceutics, 2002, 235, 159–168. 
 
58. Rajesh.k, Rajalakshmi.R, Umamaheswari.J, Ashok Kumar C.K. liquisolid  
             technique a novel approach to enhance solubility and bioavailability,  
             International Journal of Biopharmaceutics. 2011; 2(1): 8-13. 
59. Zhao.N, Augsburger L.L. The influence of swelling capacity of  
            superdisintegrants  in different pH media on the dissolution of  
              hydrochlorothiazide from directly compressed tablets. AAPS pharmasciTech,  
            2005, 6,120-126.  
 
60. Rajendran.N.N, panneerselvam.M, Natarajan.R, Selvaraj.S. A novel drug-drug  
              solid dispersion of Hydrochlorothiazide and Losartan potassium. International  
            journal of pharma and biosciences. 2010, 1, 68-80. 
 
61. Yogesh Kadama, Usha Yerramillia, Anita Bahadurb, Pratap Bahadur. Micelles  
               from PEO–PPO–PEO block copolymers as nanocontainers for solubilization  
               of a poorly water soluble drug hydrochlorothiazide. Colloids and Surfaces B:  
             Biointerfaces, 2011, 83, 49–57. 
 
62. Maria Arlete Silva Pires, Robson Saugusto Souza dos Santos and Ruben Dario  
            Sinisterra. Molecules, 2011, 16, 4482-4499. 
 
63. Martins R.M, Pereira S.V, Machado M.O, Nosari A.B.F.L, Tacon L.A,   
  
 
 
 
107 
 
            Siqueira.S and Freitas L.A.P. preparation of microparticles of  
            hydrochlorothiazide  by spray drying. 2011,26-28. 
 
64. Padmapriya S, Rajendran N.N, Ravichandran V, Comparitive studies on novel  
            Hydrochlorothiazide- Captopril solid dispersion tablets and commercial  
            tablets. International journal of pharmTech Research, 2011, 3, 1509-1514. 
 
65. Alvaro Goyanes, Consuelo Souto, Ramón Martínez-Pacheco. Co-processed  
              MCC-Eudragit_ E excipients for extrusion–spheronization. European Journal  
            of Pharmaceutics and Biopharmaceutics.2011, 79, 658–663. 
  
66. Gandhimathi.M, Vikram.K, Baskaran.A and Ravi T.K; “Simultaneous  
             estimation of Hydrochlorothiazide–Losartan potassium in UV  
             method.”Ind.J.Pharm-march 2001, 165-166. 
 
67. Parasuram S, Ravendran R, kesavan R. Blood sample collection in small  
            laboratory animals. J Pharmacol Pharmacother 2010; 1:87-93. 
 
68. Lara F.Tutunji, Maha F. Tutunji, Mamoun I. Alzoubi, Manal H. Khabbas, Adi  
              I. Arida, Simultaneous determination of irbesartan and hydrochlorothiazide in  
            human plasma using HPLC coupled with tandem mass spectroscopy:  
            Application to bioequivalance studies. Journal of pharmaceutical and  
            biomedical analysis.2010, 51, 985-990
